VG Health

Wells Fargo Raises Johnson & Johnson's Price Target to $230

LM Advisors LLC Reduces Holdings in Merck

UnitedHealth Group was named one of The Motley Fool's top 10 stocks to buy for 2026.

Morgan Stanley raises Eli Lilly's price target to $1,290

Ampergy Financial Increased Holdings in Merck & Co., Inc., Executive Reduced

Johnson & Johnson's AKEEGA® Approved by FDA for BRCA2 Mutated Prostate Cancer

UnitedHealth Group to pay quarterly dividend on December 18, 2025.

Multiple firms analyze Lilly's long-term strategy, highlighting both growth potential and high valuation risks

Moody's affirms Eli Lilly's Aa3 rating, outlook revised to positive

Seeking Alpha publishes analysis calling UnitedHealth a long-term compounder worth holding through any cycle

UnitedHealth Group to Release 2025 Financial Results and 2026 Guidance in January 2026

Market analysis suggests UNH stock may break out above the key $340 resistance level

Eli Lilly reports new data from phase 3 trial of Inluriyo for breast cancer

Truist Securities Reiterates 'Buy' Rating on Eli Lilly Stock Following Positive Trial Data

Morgan Stanley Raises Merck's Target Price to $102

Financial Giants Conduct Significant Bullish Trades in Intuitive Surgical, Citigroup Downgrades Its Rating

Wells Fargo Raises Intuitive Surgical Target Price to $654

Market Rumors Suggest Eli Lilly May Acquire French Biotech Firm Abivax

Eli Lilly Boosts Quarterly Dividend by 15.3%

EMA panel recommends expanding Eli Lilly's diabetes drug scope to children

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

On December 12, 2025, Abbott Laboratories appointed Nita Ahuja, M.D. to its Board of Directors.1On December 12, 2025, Daniel Gesua Sive Salvadori, Vice President of Abbott Laboratories, reported a gift of 1,536 shares through a Form 4 filing, bringing his total direct holdings to 132,233 shares.2

TradingView

Abbott Laboratories

Key facts: Abbott Laboratories appoints Nita Ahuja to Board; VP reports share gift

The article evaluates Eli Lilly's stock valuation amidst its significant growth, driven by obesity and diabetes treatments. Despite a 32.1% year-to-date increase, a valuation framework scores it 1/6, indicating it's expensive by traditional metrics. A DCF analysis suggests it's undervalued by 19.4%, while a PE ratio analysis finds it overvalued. The article introduces "Narratives" for a holistic valuation approach, linking company stories to financial forecasts.

Simplywall

Eli Lilly

Has Lilly’s Obesity Drug Boom Pushed Its 2025 Valuation Too Far?

Wells Fargo & Company raised its target price for Johnson & Johnson (NYSE:JNJ) from $212.00 to $230.00, giving the stock an "overweight" rating. This suggests an 8.67% potential upside from the current price. Several other firms have also updated their ratings and price targets for JNJ recently. The stock has a consensus rating of "Moderate Buy" and a consensus target price of $207.55.

Market Beat

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) Given New $230.00 Price Target at Wells Fargo & Company

ISRG

Lazard Asset Management LLC increased its stake in Intuitive Surgical, Inc. by 0.4% in Q2, now holding 589,109 shares worth $320.13 million. Other institutional investors also adjusted their positions. Insiders sold 109,043 shares worth $60.82 million in the last 90 days. Analysts have mixed ratings on ISRG, with a consensus rating of 'Moderate Buy' and a price target of $608.79. Intuitive Surgical's Q3 earnings exceeded expectations with $2.51 billion in revenue and $2.40 EPS.

Lazard

Intuitive Surgical

Lazard Asset Management LLC Increases Stock Holdings in Intuitive Surgical, Inc. $ISRG

LM Advisors LLC reduced its holdings in Merck & Co., Inc. by 42.8% in Q2, selling 11,547 shares. The firm's remaining 15,401 shares are valued at $1.22 million. Other institutional investors also adjusted their positions in Merck. Insider EVP David Williams sold 8,614 shares. Analysts have mixed ratings on Merck, with a consensus 'Hold' rating and an average target price of $107.50. Merck's recent earnings beat estimates, reporting $2.58 EPS and $17.28 billion in revenue.

Merck

LM Advisors LLC Cuts Stock Position in Merck & Co., Inc. $MRK

Ameriprise Financial Inc. reduced its stake in UnitedHealth Group by 17.8% in Q2, now holding $999.36 million worth of shares. Other hedge funds also adjusted their positions. Analysts have varied ratings on UnitedHealth, with a consensus "Hold" and an average target price of $385.54. UnitedHealth's Q3 earnings exceeded expectations, and the company announced a quarterly dividend of $2.21 per share.

Ameriprise Financial

Unitedhealth

Ameriprise Financial Inc. Has $999.36 Million Position in UnitedHealth Group Incorporated $UNH

Ameriprise Financial Inc. increased its stake in Merck & Co., Inc. by 2.3% in Q2, owning 0.53% of the company. Analysts have mixed ratings for Merck, with a consensus "Hold" and an average target price of $107.50. EVP David Michael Williams sold shares, reducing his ownership by 25.95%. Merck's stock opened at $100.33, with a market cap of $249.02 billion.

Ameriprise Financial Inc. Acquires 299,561 Shares of Merck & Co., Inc. $MRK

Adage Capital Partners GP L.L.C. reduced its stake in Intuitive Surgical, Inc. by 4.4% in Q2, now holding 369,584 shares worth $200.84 million. Other institutional investors like Vanguard, State Street, and Geode also adjusted their positions. Insider transactions included significant sales by EVP Brian Miller and CEO David Rosa. Intuitive Surgical reported strong Q3 earnings, with a 22.9% revenue increase. Analysts remain positive, with Royal Bank of Canada setting a $625 price target.

Adage Capital Partners GP L.L.C. Has $200.84 Million Stock Holdings in Intuitive Surgical, Inc. $ISRG

A California jury awarded $40 million in compensatory damages against Johnson & Johnson in a landmark talc verdict. The case involved two women who developed ovarian cancer after using J&J's talc-based products. Testimony revealed J&J concealed asbestos evidence for decades. This verdict is the first since 2021 and marks a significant milestone in ongoing litigation against J&J. Bellwether trials for over 70,000 claims are expected to begin next year.

MorningStar

California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & Johnson

A California jury awarded $40 million to two women who claimed Johnson & Johnson's baby powder caused their ovarian cancer. The jury found J&J knew its talc products were dangerous but failed to warn consumers. J&J plans to appeal the verdict. The company faces over 67,000 similar lawsuits and has attempted to resolve them through bankruptcy, which has been rejected. J&J stopped selling talc-based baby powder in the U.S. in 2020.

Reuters

Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial

FDA has approved Johnson & Johnson's AKEEGA for treating BRCA2-mutated metastatic prostate cancer. This marks the first precision medicine combination treatment for this specific mutation, advancing personalized prostate cancer treatment. The announcement was made by Johnson & Johnson, with the original content published via PR Newswire on December 13, 2025. The news brief was created by Public Technologies using AI.

FDA Approves Johnson & Johnson’s AKEEGA for BRCA2-Mutated Metastatic Prostate Cancer

California jury orders Johnson & Johnson to pay $40 million after finding company failed to warn consumers about baby powder cancer risk

marketscreener

California jury orders Johnson & Johnson to pay $40 million after finding company failed to warn consumers about baby powder cancer risk

ABBV

TXMD

TherapeuticsMD Inc. (TXMD) shares fell 4.89% to $1.75 on Friday, underperforming compared to competitors like AbbVie Inc. (ABBV), which fell 0.29%. This marks the second consecutive day of losses for TXMD, closing 28.28% below its 52-week high. The trading volume was significantly below its 50-day average. The NASDAQ Composite and Dow Jones also saw declines.

Dow Jones

Abbvie

Therapeutics MD

TherapeuticsMD Inc. Stock Underperforms Friday When Compared To Competitors